TIME- SPECIFIC DELAYED/PULSATILE RELEASE DOSAGE FORMS.

摘要

A time specific delayed/pulsatile release dosage form which comprises: a core comprising at least one active principle and at least one disintegrating agent; a sealing layer surrounding the core essentially consisting of one or more water soluble or water insoluble pH independent polymers; an outer coating essentially consisting of one or more hydrophilic pH independent polymers; wherein: the at least one disintegrating agent is present in amounts of 1-20% byweight and the at least one active principle is present in amounts of 1-80% by weight, with respect to the core; the sealing layer accounts for 0.1-10% byweight, withrespect to the core; the outer coating accounts for 5-500 % byweight, withrespect to the core. These coated cores are capable of ensuring the immediate release of the active principle after a pre-defined lag time, independently of physiological pH variations occurring in the gastro-intestinal tract of mammals. A time specific delayed/pulsatile release dosage form which comprises: a core comprising at least one active principle and at least one disintegrating agent; a sealing layer surrounding the core essentially consisting of one or more water soluble or water insoluble pH independent polymers; an outer coating essentially consisting of one or more hydrophilic pH independent polymers; wherein: the at least one disintegrating agent is present in amounts of 1-20% byweight and the at least one active principle is present in amounts of 1-80% by weight, with respect to the core; the sealing layer accounts for 0.1-10% byweight, withrespect to the core; the outer coating accounts for 5-500 % byweight, withrespect to the core. These coated cores are capable of ensuring the immediate release of the active principle after a pre-defined lag time, independently of physiological pH variations occurring in the gastro-intestinal tract of mammals. A compound of formula (I) and salts thereof are provided: wherein A is defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.